InventisBio Co., Limited

Equities

688382

CNE100005Q22

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
8.71 ^CNY	+0.46%		+2.11%	-42.47%

04-29	InventisBio Co., Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-11	Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	MT

InventisBio Co., Ltd. has completed an IPO in the amount of CNY 2.0838 billion.

July 15, 2022 at 05:00 am

InventisBio Co., Ltd. has completed an IPO in the amount of CNY 2.0838 billion.
Security Name: A Shares
Security Type: Common Stock
Securities Offered: 115,000,000
PriceRange: CNY 18.12
Transaction Features: Sponsor Backed Offering

Latest news about InventisBio Co., Limited

InventisBio Co., Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	04-11	MT
InventisBio Co., Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-05	CI
InventisBio Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
InventisBio, Beida Pharmaceutical Get Registration Certification for Befortinib Mesylate Capsules	13/10/23	MT
InventisBio Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	21/08/23	CI
InventisBio Grants Rights of D-1553 to Chia Tai Tianqing	04/08/23	MT
Sino Biopharm Unit Gets Exclusive License to Develop Inventisbio's Cancer Drug	03/08/23	MT
Chia-Tai Tianqing Pharmaceutical Group Co., Ltd Enters into Exclusive License and Cooperation Agreement with Inventisbio Co., Ltd	03/08/23	CI
Certain A Shares of InventisBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 25-JUL-2023.	24/07/23	CI
InventisBio Co., Ltd.(SHSE:688382) added to Shanghai Stock Exchange Composite Index	24/07/23	CI
InventisBio Co., Ltd.(SHSE:688382) added to Shanghai Stock Exchange A Share Index	24/07/23	CI
InventisBio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
InventisBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
InventisBio Co., Ltd. has completed an IPO in the amount of CNY 2.0838 billion.	15/07/22	CI

Chart InventisBio Co., Limited

Duration

Period

More charts

Company Profile

InventisBio Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main product is still in clinical development. The Company's core products mainly focus on major disease areas such as oncology and metabolic diseases. The Company's products include D-0120, D-0502, D-1553, BPI-D0316 and others.

Sector

Biotechnology & Medical Research

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for InventisBio Co., Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.71 CNY

Average target price

18.5 CNY

Spread / Average Target

+112.40%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INVENTISBIO CO., LIMITED	-42.47%	694M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs